PART ONE: LECTURES
Welcome and Introduction
Peter van de Kerkhof
Precision Medicine, Including Early Active Intervention
Christopher Griffiths
Cutting Edge Topical Medications
Linda Stein Gold
Cutting Edge Systemic Treatments: Oral and Biologic
Alexander Egeberg
Considering Comorbidities in Treatment Planning
Andrew Blauvelt
Panel Discussion
Linda Stein Gold, facilitator
BREAK
PART TWO: CHALLENGING CASES
Challenging Case 1: A Patient with GPP
Jaquelini Barboza da Silva
Challenging Case 2: A Patient with Multiple Comorbidities
Álvaro González-Cantero
Challenging Case 3: A Patient with Active Cancer
Matt Vesely
Q & A – Speaker Panel
Peter van de Kerkhof, facilitator
CLOSING COMMENTS AND ADJOURN
Peter van de Kerkhof
The content of this session and opinions expressed by presenters are those of the respective presenting society or presenters and do not represent an endorsement by, nor imply that the session content has been evaluated or approved by the American Academy of Dermatology or corporate sponsors.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
